Comparative effect of statins on the risk of incident Alzheimer disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 20, 2017
- Accepted in final form September 19, 2017
- First Published December 15, 2017.
Article Versions
- Previous version (December 15, 2017 - 12:40).
- You are viewing the most recent version of this article.
Author Disclosures
- Liliya Sinyavskaya, MD, MPH,
- Serge Gauthier, MD,
- Christel Renoux, MD, MSc, PhD,
- Sophie Dell'Aniello, MSc,
- Samy Suissa, PhD and
- Paul Brassard, MD, MSc
- Liliya Sinyavskaya, MD, MPH,
NONE
NONE
(1)Non-profit organization Canadian Network for Observational Drug Effect Studies (CNODES), A scholarships for participation and poster presentation at the 33rd ICPE International Conference of Pharmacoepidemiology and therapeutic Risk Management
NONE
NONE
NONE
NONE
NONE
NONE
(1)Non-profit organization Canadian Network for Observational Drug Effect Studies (CNODES), A scholarships for participation in the University of McGill summer courses on pharmacoepidemiology (Montreal, Canada) (2)Non-profit organization Canadian Network for Observational Drug Effect Studies (CNODES), PhD scholarship (3)Non-profit organization National Institute of Health, US Department of Health and Human Services. Fogarty International Center. Fogarty international training and research program. Graduate scholarship for MPH program
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Serge Gauthier, MD,
DSMB (1) Commercia entity: Eisai (2) Non-commercial entities: ATRI, ADCS, Banner-Health Scientific advisor, commercial entities: Boeringer- Ingelheim, TauRx, Lilly
NONE
(1) Commercial entity support for lectures at International congress: Schwabe
Alzheimer's & Dementia, member of editorial board, 2017-, no compensation
NONE
NONE
NONE
1. Non-profit entity: Kalgene
NONE
NONE
NONE
Commercial entities: Lundbeck, Roche, Lilly
CIHR grant support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christel Renoux, MD, MSc, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sophie Dell'Aniello, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Samy Suissa, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paul Brassard, MD, MSc
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Centre for Clinical Epidemiology (L.S., C.R., S.D., S.S., P.B.), Jewish General Hospital; McGill University Research Centre for Studies in Aging (S.G.), Douglas Mental Health University Institute; and Departments of Neurology and Neurosurgery (C.R.) and Medicine and Epidemiology, Biostatistics, and Occupational Health (C.R., S.S., P.B.), McGill University, Montreal, Canada.
- Correspondence
Dr. Brassard paul.brassard{at}mcgill.ca
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Editorial
Statin use and risk of Alzheimer diseaseA new view on an old relationshipSevil Yasar, Rachel Whitmer et al.Neurology, December 15, 2017 -
Article
Discontinuation of statin therapy associates with Parkinson diseaseA population-based studyYen-Chieh Lee, Chin-Hsien Lin, Ruey-Meei Wu et al.Neurology, July 24, 2013 -
Articles
Statin therapy and risk of dementia in the elderlyA community-based prospective cohort studyG. Li, R. Higdon, W. A. Kukull et al.Neurology, November 08, 2004 -
Editorial
Holding on to statins in Parkinson diseaseEng-King Tan, Louis C.S. Tan et al.Neurology, July 24, 2013